Format

Send to

Choose Destination
Rev Saude Publica. 2009 Aug;43 Suppl 1:62-9.

Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.

Author information

1
Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina (UFSC), 88040-970 Florianópolis, SC, Brasil.

Abstract

OBJECTIVE:

To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia.

METHODS:

A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Unico de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature.

RESULTS:

The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives.

CONCLUSIONS:

Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Unico de Saúde.

PMID:
19669066
DOI:
10.1590/s0034-89102009000800010
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center